Hongbin Gu

On Setting Response Criteria for Calibrated Subjective Probability Estimates.

Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function.

Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.

Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia.

Antipsychotic drug effects on brain morphology in first-episode psychosis.

Facial emotion perception and fusiform gyrus volume in first episode schizophrenia.

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.

A longitudinal study of neurocognitive function in individuals at-risk for psychosis.

Asymmetrical ventricular enlargement in Parkinson's disease.

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Feasibility and diagnostic validity of the M-3 checklist: a brief, self-rated screen for depressive, bipolar, anxiety, and post-traumatic stress disorders in primary care.

Incidence, risk factors for amputation among patients with diabetic foot ulcer in a Chinese tertiary hospital.

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

Simultaneous measurements of multiple flow parameters for scramjet characterization using tunable diode-laser sensors.

Differences in White Matter Fiber Tract Development Present From 6 to 24 Months in Infants With Autism.

Quantitative tract-based white matter development from birth to age 2years.

Brain volume findings in 6-month-old infants at high familial risk for autism.

Associations between white matter microstructure and infants' working memory.

Differences in subcortical structures in young adolescents at familial risk for schizophrenia: a preliminary study.

Frontolimbic neural circuitry at 6 months predicts individual differences in joint attention at 9 months.

Altered fronto-limbic activity in children and adolescents with familial high risk for schizophrenia.

White Matter Microstructure and Atypical Visual Orienting in 7-Month-Olds at Risk for Autism.

Reduced delta power and synchrony and increased gamma power during the P3 time window in schizophrenia.

Longitudinal patterns of repetitive behavior in toddlers with autism.

Repetitive behavior in 12-month-olds later classified with autism spectrum disorder.

Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells.

Impact of dexmedetomidine versus propofol on cardiac function of children undergoing laparoscopic surgery.

Comparison of Adrenal Suppression between Etomidate and Dexmedetomidine in Children with Congenital Heart Disease.

Behavioral, cognitive, and adaptive development in infants with autism spectrum disorder in the first 2 years of life.

Splenium development and early spoken language in human infants.

Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones.